Cited by

• Human Fibrinogen: Molecular and Genetic Aspects of Congenital Disorders.

  Tiscia GL, Margaglione M. Tiscia GL, et al. Int J Mol Sci. 2018 May 29;19(6):1597. doi: 10.3390/ijms19061597. Int J Mol Sci. 2018. PMID: 29844251 Free PMC article. Review.
• Comprehensive transcriptional landscape of porcine cardiac and skeletal muscles reveals differences of aging.

  Chen J, Zou Q, Lv D, Wei Y, Raza MA, Chen Y, Li P, Xi X, Xu H, Wen A, Zhu L, Tang G, Li M, Jiang A, Liu Y, Fu Y, Jiang Y, Li X. Chen J, et al. Oncotarget. 2017 Dec 15;9(2):1524-1541. doi: 10.18632/oncotarget.23290. eCollection 2018 Jan 5. Oncotarget. 2017. PMID: 29416711 Free PMC article.
• First-Line Administration of Fibrinogen Concentrate in the Bleeding Trauma Patient: Searching for Effective Dosages and Optimal Post-Treatment Levels Limiting Massive Transfusion-Further Results of the RETIC Study.

  Innerhofer N, Treichl B, Rugg C, Fries D, Mittermayr M, Hell T, Oswald E, Innerhofer P, On Behalf Of The Retic Study Group. Innerhofer N, et al. J Clin Med. 2021 Aug 31;10(17):3930. doi: 10.3390/jcm10173930. J Clin Med. 2021. PMID: 34501379 Free PMC article.
• Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges.

  Gaule TG, Ajjan RA. Gaule TG, et al. Int J Mol Sci. 2021 Jun 28;22(13):6916. doi: 10.3390/ijms22136916. Int J Mol Sci. 2021. PMID: 34203139 Free PMC article. Review.
• Combined Administration of Fibrinogen and Factor XIII Concentrate Does Not Improve Dilutional Coagulopathy Superiorly Than Sole Fibrinogen Therapy: Results of an In-Vitro Thrombelastographic Study.

  Schneck E, Muelich M, Markmann M, Edinger F, Cooper N, Moeller A, Bein G, Hecker A, Koch C, Sander M, Wolff M. Schneck E, et al. J Clin Med. 2021 May 12;10(10):2068. doi: 10.3390/jcm10102068. J Clin Med. 2021. PMID: 34065924 Free PMC article.